Study of Pharmacokinetic Interaction Between Combivir® (ZDV+3TC) and BILR 355 BS Plus Ritonavir.

Trial Profile

Study of Pharmacokinetic Interaction Between Combivir® (ZDV+3TC) and BILR 355 BS Plus Ritonavir.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Oct 2014

At a glance

  • Drugs BILR 355 BS (Primary) ; Lamivudine/zidovudine; Ritonavir
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 13 Feb 2012 New trial record
    • 01 Feb 2012 Results published in the Journal of Clinical Pharmacy and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top